血管化复合同种异体移植的干细胞治疗进展  

Stem cell therapy on vascular composite allotransplantation

作　　者：王晨羽[1] 王晓军[1] 龙笑[1] Wang Chenyu;Wang Xiaojun;Long Xiao(Department of Plastic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,State Key Laboratory of Complex Severe and Rare Diseases(Peking Union Medical College Hospital),Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院整形外科,疑难重症及罕见病国家重点实验室,100730

出　　处：《中华整形外科杂志》2021年第6期692-695,共4页Chinese Journal of Plastic Surgery

基　　金：科技部战略性国际科技创新合作重点专项(2019YFE020215);国家自然科学基金面上项目(81670444)。

摘　　要：血管化复合同种异体移植是指来自不同胚层的多种组织构成的复合移植,可显著提高患者术后外形、功能和生活质量。皮肤排斥是血管化复合同种异体移植免疫不耐受的关键,术后需长期使用免疫抑制剂,因此导致多种急性和慢性并发症,是目前血管化复合同种异体移植广泛应用的主要障碍。干细胞的营养和旁分泌作用,抑制炎症反应和免疫抑制调节特性,在血管化复合同种异体移植免疫耐受的相关研究中得到了广泛关注。该文对当前血管化复合同种异体移植的干细胞治疗的研究进展进行综述,为开展相关研究提供参考。Vascular composite allotransplantation(VCA)is a composite transplantation composed of various tissues from different germ layers,which can significantly improve the living condition of patients.Skin repulsion plays a crucial role in VCA immune intolerance.Long-term use of immunosuppressive agents post-operatively leads to a variety of acute and chronic complication,which currently is the main obstacle to the widespread use of VCA.The function of secretion,inhibition of inflammatory response and immunosuppressive regulation properties of stem cells has received significant attention in VCA immune intolerance studies.This article reviewed the current research progress of stem cell therapy for VCA,providing a reference for relevant research.

关 键 词：同种异体皮肤移植 血管化复合移植 免疫机制 干细胞治疗 

分 类 号：R654.4[医药卫生—外科学]